RGLS REGULUS THERAPEUTICS INC Company Mergers 8-K Filing 2025 - Merger of Equals On April 29, 2025, Regulus Therapeutics Inc. announced a merger agreement with Novartis AG in which Novartis will acquire all shares at $7.00 per share plus contingent value rights potentially worth an additional $7.00, subject to conditions. The company also confirmed that the board unanimously supports this merger as beneficial for shareholders.Get access to all SEC 8-K filings of the REGULUS THERAPEUTICS INC